ArticleThe oncologist2025

Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study.

Yvonne Bach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.